文献速递免疫规划妇幼与学校卫生

三价B族链球菌疫苗在孕妇及婴儿中的安全性和免疫原性:随机安慰剂对照II期试验

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.
PubMed 文献 · Vaccine · 2020-09-01

该随机、观察者盲法、安慰剂对照II期试验在美国18-40岁健康孕妇中评估三价B族链球菌(GBS)疫苗的安全性、免疫原性及母体抗体经胎盘转移和婴儿抗体持久性。结果显示疫苗组严重不良事件发生率与安慰剂组相似,未发现疫苗相关严重不良事件;疫苗组血清型特异性IgG几何平均浓度在接种后第31天较安慰剂组高13-23倍,并持续至产后第90天,婴儿IgG和母乳sIgA几何平均浓度在各时间点均高于安慰剂组。结论认为母体免疫具有良好安全性,可诱导抗体经胎盘转移并在婴儿体内至少持续3个月。

要点

  • 孕妇接种三价GBS疫苗安全性良好,未发现疫苗相关严重不良事件。
  • 疫苗诱导的血清型特异性IgG在接种后第31天较安慰剂组高13-23倍,持续至产后第90天。
  • 婴儿IgG和母乳sIgA几何平均浓度在疫苗组各时间点均高于安慰剂组。

核心结论

  • 孕妇接种三价GBS疫苗安全性良好,可诱导抗体经胎盘转移并在婴儿体内至少持续3个月。

研究设计与样本

  • 随机、观察者盲法、安慰剂对照II期试验,纳入18-40岁健康孕妇,孕240/7-346/7周接种一剂三价GBS疫苗(n=49)或安慰剂(n=26)。
  • 研究于2014年3月至2015年8月在美国开展,安全性随访至产后第180天。
  • 主要免疫原性目标为评估血清型Ia/Ib/III特异性IgG水平、抗体转移比及母乳中sIgA和IgG。
  • 计划样本量未基于统计假设,为描述性研究。

主要发现

  • 严重不良事件报告率:疫苗组孕妇16%、其婴儿15%;安慰剂组孕妇15%、其婴儿12%;均无致死性或疫苗相关事件。
  • 疫苗组血清型特异性IgG几何平均浓度在接种后第31天较安慰剂组高13-23倍,并持续至产后第90天。
  • 疫苗组抗体转移比(脐带血/分娩时母体血清)为0.62-0.82。
  • 婴儿IgG几何平均浓度和母乳sIgA几何平均浓度在疫苗组各时间点均高于安慰剂组。
  • 接种前可检测到抗体浓度的女性,其接种后抗体中位浓度显著更高。

临床怎么用

  • 孕期接种三价GBS疫苗可能通过胎盘抗体转移为婴儿提供被动免疫保护,但需进一步III期试验确认效力。

局限性

  • 样本量较小(疫苗组49例,安慰剂组26例),计划样本量未基于统计假设,为描述性研究。
  • 研究仅在美国开展,人群代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the safety and immunogenicity of an investigational trivalent group B streptococcus (GBS) vaccine in US pregnant women, transplacental serotype-specific antibody transfer and persistence in infants, and serotype-specific antibodies in breast milk. METHODS: This randomized, observer-blind, placebo-controlled trial administered one dose of trivalent GBS vaccine (n = 49) or placebo (n = 26) to healthy pregnant 18-40-year-old women at 240/7-346/7 weeks' gestation. Women were enrolled from March 2014 to August 2015. Safety follow-up continued through postpartum day 180. Primary immunogenicity objectives were to evaluate serotype Ia/Ib/III-specific immunoglobulin G (IgG) levels in sera from women on day 1 (pre-vaccination), day 31, delivery and postpartum days 42 and 90, and from infants at birth (cord blood), days 42 and 90. Antibody transfer ratios (cord blood/maternal sera at delivery) and serotype-specific secretory immunoglobulin A (sIgA) and IgG in breast milk after delivery and on postpartum days 42 and 90 were evaluated. The planned sample size was not based on statistical assumptions for this descriptive study. RESULTS: Baseline characteristics were similar between groups. Serious adverse events were reported for 16% of GBS-vaccinated women and 15% of their infants, and 15% of placebo recipients and 12% of their infants; none were fatal or deemed vaccine-related. Serotype-specific IgG geometric mean concentrations (GMCs) were 13-23-fold higher in vaccine vs placebo recipients on day 31 and persisted until postpartum day 90. Median antibody concentrations were substantially higher in women with detectable pre-vaccination antibody concentrations. Antibody transfer ratios in the vaccine group were 0.62-0.82. Infant IgG GMCs and breast milk sIgA GMCs were higher in the vaccine vs the placebo group at all timepoints. CONCLUSIONS: Maternal immunization with the trivalent GBS vaccine in US women had a favorable safety profile, elicited antibodies that were transplacentally transferred and persisted in infants for a minimum of 3 months. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, NCT02046148.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Swamy GK, Metz TD, Edwards KM, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial. Vaccine. 2020. PMID: 32883555. doi:10.1016/j.vaccine.2020.08.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。